TORONTO, CANADA--(Marketwired - Mar 10, 2014) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.
Luke Beshar is Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals. He joined the company in 2007 and has been responsible for financial management, investor relations, information technology, technical operations, supply- chain management, facilities, project management, contracts & outsourcing, and alliance management. Mr. Beshar has utilized his 30 years of experience and strategic and financial expertise to help transform NPS into a global biopharmaceutical company that is bringing innovative therapies to patients with rare diseases around the world. Under his financial leadership, NPS secured approximately $400M of capital and its market capitalization increased from $180 million to more than $3 billion. Prior to joining NPS, Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a global life sciences company. At Cambrex, his accomplishments included raising approximately $600 million of new capital, building a high performance global finance team, and leading a process of evaluating strategic alternatives, which resulted in the sale of non-strategic operations for $460 million and an $11 per share special dividend to shareholders. Mr. Beshar began his career with Arthur Andersen & Co. and is a certified public accountant. He obtained his bachelor's degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.
Dr. Thomas Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS®. From 2002 to 2007, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM®. Previously, he was Vice President, Clinical Affairs at Targeted Genetics, and before that he was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.
Stem Cell Therapeutics (SCT) also announced that two long-serving directors, Mr. Dean Peterson and Dr. James DeMesa, have retired from the Board.
"We are appreciative of the strong support and contributions from Dean and James in the past, particularly in the recent period when we jointly undertook to transform the company. Dean Peterson was the architect behind the reformation of the company and helped recruit the board that has undertaken this task. We are grateful to him and James for their integrity and enthusiasm" remarked SCT's Chairman, Dr. Calvin Stiller. "The addition of Mr. Beshar and Dr. Reynolds, two highly accomplished professionals, to the Board provides us with invaluable skills and expertise in finance and clinical development, areas of critical importance to our future success. The composition of the current Board reflects our new strategic goals, our new focus on immunotherapy and oncology, as well as our new US institutional investor-base and capital markets aspirations."
"We have promising assets, an exceptional management team, a board second to none, and we are well funded. As I leave the board I have an elevated level of confidence in our successful pursuit of value creation," commented Mr. Peterson.
The company also announced that the Board of Directors has granted options to purchase 200,000 common shares of the Corporation to each of the newly appointed directors. The options were issued at an exercise price of $0.63 per share for a ten-year term. The grant of options is subject to acceptance by the TSX Venture Exchange.
About Stem Cell Therapeutics:
Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing cancer stem cell discoveries into novel and innovative cancer therapies. Building on over half a century of leading and groundbreaking Canadian stem cell research, the company is supported by established links to a group of prominent Toronto academic research institutes and cancer treatment centers, representing one of the world's most acclaimed cancer research hubs. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and several other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage programs include the recently in-licensed program focused on the structure of tigecycline, which is currently being evaluated in a multi-centre Phase I study in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer stem cell asset that recently completed a 28-patient Phase I trial in interstitial cystitis ("IC") patients. For more information, visit: www.stemcellthera.com
Caution Regarding Forward-Looking Information:
This press release may contain forward-looking statements, which reflect SCT's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in SCT's ongoing quarterly and annual reporting. Except as required by applicable securities laws, SCT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Health Care Industry
- Investment & Company Information
- Board of Directors
- Executive Vice President
- TSX Venture Exchange